ABC News: How AI is Shaping the Future of Drug Discovery
In an ABC News interview, Phil Mounteney, VP at Dotmatics, explains how AI is rapidly transforming pharmaceutical R&D by accelerating drug discovery, lowering costs, aiding COVID-19 vaccine development, influencing FDA regulatory guidance, enhancing predictive capabilities in pharma, and how Dotmatics' Luma platform is driving this scientific intelligence revolution.
ABC News: How AI is Shaping the Future of Drug Discovery
Artificial intelligence is changing the game in pharmaceutical R&D—and it's happening faster than most people think. In a recent interview with a California ABC News affiliate, Phil Mounteney, Vice President at Dotmatics, shares how AI is helping pharma companies accelerate drug discovery, reduce development costs, and bring safer, more effective treatments to patients, faster.
“If we can reduce the time and cost to bring a drug to market, we can get drugs to patients more quickly and affordably.” – Phil Mounteney, VP Science & Technology at Dotmatics
In this conversation, Phil also explains:
-
How AI helped develop the COVID-19 vaccine
-
Why the FDA is already incorporating AI into regulatory guidance
-
How the pharma industry is becoming more predictive
-
What the Luma platform is doing to power this transformation
Watch the full interview to see how Dotmatics is helping shape the future of medicine through scientific intelligence.
Learn More About Dotmatics
Schedule a meeting with our team to learn more about Luma's AI capabilities.